Health guide
Weight and metabolism
Losing weight with medical support: the evidence on GLP-1 therapies, eligibility, side effects and realistic expectations.
8 articles
- 5.0 out of 5 stars from 2,039 Google reviews
- 13,982 patients treated
- Licensed physicians
- German, English, Turkish, Arabic
All articles on Weight and metabolism
-
Getting a weight loss injection prescribed: eligibility and insurance
Weight loss injections are prescription-only and can be prescribed by any licensed doctor, including by video consultation. They may be considered … -
Mounjaro (tirzepatide): effect, evidence, dosing and side effects
Mounjaro is the brand name of tirzepatide, a once-weekly injection that acts on two gut hormone receptors, GIP and GLP-1. In the approval trial, … -
Ozempic (semaglutide): diabetes, weight loss, off-label and shortages
Ozempic is the brand name of semaglutide at the doses used for type 2 diabetes, up to 2 mg a week. It is not approved for weight loss without … -
Stopping weight loss injections: regain, evidence and what helps
After stopping weight loss injections, most people regain a large part of the weight they lost. One year after ending semaglutide, on average two … -
Wegovy (semaglutide 2.4 mg): effect, evidence, dosing and eligibility
Wegovy is the brand name of semaglutide 2.4 mg, a GLP-1 receptor agonist for weight management injected once a week. In the approval trial, adults … -
Wegovy or Mounjaro? Semaglutide and tirzepatide compared
Wegovy contains semaglutide, which acts on the GLP-1 receptor; Mounjaro contains tirzepatide, which also acts on the GIP receptor. In a head-to-head … -
Weight loss injection side effects: common, rare and warning signs
The most common side effects of weight loss injections are nausea, diarrhoea, vomiting and constipation, usually mild and during dose escalation. … -
Weight loss injections: how they work, the evidence, costs, eligibility and side effects
The weight loss injection is a weekly injected active substance from the group of GLP-1 receptor agonists, semaglutide or tirzepatide. In approval …